Highlights from the 12th World Conference on Lung Cancer - CME
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA; David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN; David Jackman, MD, Dana-Farber Cancer Institute, Boston, MD.

12th World Conference on Lung Cancer: Updates in the Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) - CME
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA

12th World Conference on Lung Cancer: Advances in the Management of Advanced NSCLC: Are We Making Progress? - CME
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN

12th World Conference on Lung Cancer: Malignant Pleural Mesothelioma Updates - CME
David Jackman, MD, Dana-Farber Cancer Institute, Boston, MA

12th World Conference on Lung Cancer: Advances in the Management of Small-Cell Lung Cancer (SCLC) - CME
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN

Preoperative PET-CT Reduces Number of Thoracotomies but Does Not Improve Survival of Patients with NSCLC (7/2/2009)
Researchers from Denmark have reported that “The use of PET-CT for preoperative staging of NSCLC [non–small cell lung cancer] reduced both the total number of thoracotomies and the number of futile thoracotomies but did not affect overall mortality.” The details of this study appeared in the July 2, 2009 issue of the New England Journal of Medicine.

Lung Cancer Screening with Low-dose Computed Tomography Associated with High Rate of False Positives (6/12/2009)
Researchers from the National Institutes of Health have reported that individuals who undergo lung cancer screening with low-dose computed tomography (LDCT) are at a high risk for receiving false-positive results. The details of this study were presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida, on May 30.

Zactima™ Shows Promise Against Non–Small Cell Lung Cancer (6/8/2009)
Researchers affiliated with the ZODIAC international Phase III clinical trial have reported that the addition of Zactima™ (vandetanib) to Taxotere® (docetaxel) delayed time to progression among patients with previously treated, advanced non–small cell lung cancer (NSCLC). The details of this study were presented on May 30 at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.

Combined Hormone Replacement Therapy Linked to Increased Death Rate from NSCLC (6/5/2009)
Researchers affiliated with the Women’s Health Initiative (WHI) have reported that menopausal women with non–small cell lung cancer (NSCLC) who receive combined hormone replacement therapy (HRT) with estrogen plus progestin are 61% more likely to die from the disease than their counterparts who received placebo. The details of this study were presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida on May 30.

Study Assesses Risk of Gastrointestinal Perforation in Patients Treated with Avastin® (6/1/2009)
Researchers from Stony Brook University Medical Center have reported that gastrointestinal perforation is a potentially serious side effect of Avastin® (bevacizumab). The details of this study appeared in the June, 2009 issue of Lancet Oncology.